At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
Goserelin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for Patients With High-Risk Localized Prostate Cancer Prior to Radical Prostatectomy
In Brief
A Phase 2 clinical trial evaluating Goserelin, Prednisone, and 2 other interventions for Prostate Cancer. Completed, enrolled 64 participants across 1 site.
Detailed Summary
This is a randomized study to evaluate the efficacy and safety neoadjuvant androgen deprivation therapy with goserelin and abiraterone with or without apalutamide prior to radical prostatectomy for patients diagnosed with localized high-risk prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesBrazil
CollaboratorsJanssen, LP
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJan 2019
Primary CompletionApr 2022
Study CompletionAug 2022
TodayJul 2026
First PostedJun 3, 2016
Enrollment StartJan 24, 2019
Primary CompletionApr 30, 2022
Study CompletionAug 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 10.1 years ago
Interventions
Goserelindrug
Androgen Deprivation Therapy
Prednisonedrug
Corticosteroid
Abirateronedrug
CYP17 inhibitor
Apalutamidedrug
Androgen-receptor antagonist